Journal
CLINICAL MEDICINE INSIGHTS-ONCOLOGY
Volume 5, Issue -, Pages 23-34Publisher
SAGE PUBLICATIONS LTD
DOI: 10.4137/CMO.S5072
Keywords
amrubicin; amrubicinol; topoisomerase II inhibitor; sensitive relapse; refractory relapse; second-line chemotherapy
Categories
Funding
- Ministry of Education, Science, Sports, and Culture of Japan [60]
Ask authors/readers for more resources
Lung cancer is the leading cause of cancer death, and approximately 15% of all lung cancer patients have small-cell lung cancer (SCLC). Although second-line chemotherapy can produce tumor regression, the prognosis is poor. Amrubicin hydrochloride (AMR) is a synthetic anthracycline anticancer agent and a potent topoisomerase II inhibitor. Here, we discuss the features of SCLC, the chemistry, pharmacokinetics, and pharmacodynamics of AMR, the results of in vitro and in vivo studies, and the efficacy and safety of AMR monotherapy and combination therapy in clinical trials. With its predictable and manageable toxicities, AMR is one of the most attractive agents for the treatment of chemotherapy-sensitive and -refractory relapsed SCLC. Numerous studies are ongoing to define the applicability of AMR therapy for patients with SCLC. These clinical trials, including phase III studies, will clarify the status of AMR in the treatment of SCLC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available